1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Cancer Market Trends

Vital Signs The Analyst's Perspective - October 2015 Issue

  • December 2015
  • 5 pages
  • Frost & Sullivan
Report ID: 3461089

Summary

Table of Contents

2015 Mammogram Guidelines Have Changed
Source: Journal of American Medical Association, October 20, 2015
On October 20, 2015, the American Cancer Society (ACS) announced an update to its recommended breast cancer screening guidelines for women with average risk of breast cancer. In the new guidelines, the ACS
recommended that “most women should begin annual screening at age 45 instead of age 40, and switch to every other year at age 55.” Mammograms can yield false-positive results, requiring additional testing or over
testing. Also, mammograms can detect very low-risk cancers that would never cause women health problems had they never been treated, resulting in many women receiving treatment who would not have otherwise
needed it, hence, over treatment.

The Analyst’s Perspective by Barbara Gilmore, Senior Industry Analyst, Life Sciences
The ACS is recommending screening for various cancers in an effort to detect cancers early, when they are easier to treat and cure. Breast cancer is the second-leading cause of cancer death in women in the United
States, and preventative screening can be beneficial. The sooner cancers can be diagnosed and treated, the higher the chance of survival or cure. In the US, there are different screening recommendations coming
from different organizations. In 2009, the US Preventative Services Task Force (USPSTF) recommended and currently recommends that women do not start getting breast mammograms until age , and then only get
screened every two years, because too many screens may lead to over diagnosis and over treatment. The ACS recommends women should be screened more frequently based on their belief that screening catches cancers at earlier stages.

What does this mean? In the long run, large sums of money will be saved with the reduced numbers of mammograms and unnecessary over treatments. Until 2015, most studies of breast cancer screening had
been performed on women older than years in the Medicare population. In 2015, physicians at Harvard Medical School and Boston Children’s studied the costs of false-positive mammograms and breast cancer over
diagnoses among women aged , based on expenditure data from a major US healthcare insurance plan for the years 2011-2013. The costs associated with false-positive mammograms and over diagnoses were
reported to be in excess of $ billion per year. It is important for women to recognize the risk factors for breast cancer, including a genetic predisposition, breast density, and family history, in making decisions about
how frequently they would have breast screens. Knowledge of the total picture will help physicians make their patient care more personalized. The women who are most at risk and would benefit from the screening should be screened. The costs associated with screening and over treatment are substantial. How much money will be saved? Time will tell.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 60 Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

Veronica helps you find the right report:

Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

Purchase Reports From Reputable Market Research Publishers

Non-small cell lung cancer (NSCLC) disease forecast and market analysis to 2035

  • $ 22000
  • Industry report
  • March 2017
  • by Datamonitor Healthcare

Disease Overview Lung cancer is a disease in which the cells in lung tissue grow uncontrollably. More than 80% of lung cancers are non-small cell lung cancers (NSCLC), with the exact proportion depending ...

Renal cell cancer (RCC) disease forecast and market analysis to 2035

  • $ 22000
  • Industry report
  • March 2017
  • by Datamonitor Healthcare

Disease Overview Renal cell cancer (RCC) is a tumor that originates in the renal cortex, the outer part of the kidney between the renal capsule and the renal medulla. Around 85% of all malignant kidney ...

Frontier Pharma: First-in-Class Innovation in Hematological Cancers - Cytokine Signaling and Kinase Targeted Immunotherapies Dominate a Large and Highly Versatile Pipeline

  • $ 6995
  • Industry report
  • May 2017
  • by GBI Research

Frontier Pharma: First-in-Class Innovation in Hematological Cancers - Cytokine Signaling and Kinase Targeted Immunotherapies Dominate a Large and Highly Versatile Pipeline Summary Hematological cance ...


ref:plp2015

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.